Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis

Jonathan Q Tran1 Clinical Pharmacology, Biogen, Cambridge, MA, USACorrespondence[email protected]

Ahmed A Othman2 Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA;3 Faculty of Pharmacy, Cairo University, Cairo, Egypt

Alvydas Mikulskis4 Global Biomarker Discovery and Development, Cambridge, MA, USA

Paul Wolstencroft5 Global Clinical Operation, Biogen, Maidenhead, Berkshire, UK

Jacob Elkins6 Global Clinical Development, Biogen, Cambridge, MA, USA

References

BielekovaBDaclizumab therapy for multiple sclerosisNeurotherapeutics2013101556723055048
PubMed Web of Science ®Google Scholar
KapposLSelmajKArnoldDLPrimary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. interferon β-1a in RRMS patients [FC1.1]Mult Scler201420Suppl 138
Google Scholar
SelmajKKapposLArnoldDLSafety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study [P094]Mult Scler201420Suppl 1109
Google Scholar
OthmanAATranJQTangMTDuttaSPopulation pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administrationClin Pharmacokinet2014531090791825212703
PubMed Web of Science ®Google Scholar
PolmanCHReingoldSCEdanGDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Ann Neurol200558684084616283615
PubMed Web of Science ®Google Scholar
GoldRGiovannoniGSelmajKDaclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialLancet201338198842167217523562009
PubMed Web of Science ®Google Scholar